IBM Corp. says it has agreed to buy equipment from a British company that it says will help improve its ability to detect the illness of Alzheimer’s disease patients.
The deal, announced Tuesday, will buy an array of diagnostic devices, computers, software and other equipment from BioMed Biotech, which specialises in studying the disease.
BioMed Biotechnology’s products have helped identify more than 5,000 Alzheimer’s patients.
The company is currently based in the U.K., but it has expanded into the U, U.S., Canada and Australia.
The agreement comes a year after IBM said it was looking to acquire a U.N. research centre for Alzheimer’s research.
IBM said the company was already in discussions with the Unautha Centre in Finland, which runs the European Centre for Disease Prevention and Control (ECDC).
The new purchase is IBM’s fourth in three years, and it will be the company’s second in the past year to buy technology from a UNAUTHA centre.
In November, it announced plans to acquire Biomedical Research Laboratories, an American company that specialises both in Alzheimer’s and other diseases.IBM is also expanding its efforts to tackle the problem of drug-resistant bacteria, which are resistant to existing drugs.
In March, the company announced it would build a new $1.3 billion biosafety centre, a facility to research new drugs that will be developed for the disease, which affects about 1.4 million people in the United States.
IBM said in November that it would spend $1 billion on its new biosafety hub, which is set to open in 2020. For more: